Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab Manufacturing Process Comparison in Healthy Adults
NCT05074459Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eptinezumab in migraine (2 arms), sponsored by Lundbeck. Primary endpoint: Area Under the Plasma Concentration-Time Curve From Zero to Infinity. Started Sep 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05074459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074459.